of dystrophin at the protein level. While dystrophin Antibodies to dystrophin have increased accuracy in antibody-based immunoblot analysis is thought to be the diagnosis of Duchenne/Becker muscular dystrophy extremely specific, unrecognized technical artifacts (D/BMD). Both typical and 'atypical' presentations of may lower the specificity. Indeed, it is possible that in this disease can be confirmed by demonstrating quali-some cases abnormal protein levels may simply reflect tative and quantitative defects in the expression of in vitro degradation of dystrophin rather than a disease dystrophin protein. However, owing to the propensity process per se: Dystrophin having been previously demfor dystrophin degradation in vitro, caution needs to onstrated to be extremely labile in muscle biopsies after be applied while performing and interpreting antisolubilization 8, 9 . In this report we identify two cases ing has led to the recognition that the phenotypic range three maternal generations there had been various undiagnosed of this disease is considerably wider than previously complaints involving the neuromuscular system. Physical examinabelieved [1] [2] [3] [4] [5] [6] [7] . Current DNA-based tests can detect ge-tion revealed normal muscle bulk and strength, however, deep tendon reflexes were hypoactive. Laboratory evaluation included elecnetic mutations in only Ç65% of D/BMD cases while tromyography which was normal and histopathological studies on the sensitivity of antibody-based tests that analyzes quadriceps muscle biopsy which revealed mild type 1 fiber grouping the protein, approaches 100%. Thus the laboratory ver-on light microscopy. No significant ultrastructural abnormalities ification of D/BMD in Ç35% of cases, relies solely upon were noted on electron microscopy. Serum chemistry revealed a mild elevation of Creatine kinase 58 IU (normal õ30 IU; EC 2.7.3.2). No the demonstration of a dystrophinopathy: a quantitadeletions of the D/BMD gene were detected by PCR-based genetic tive and/or qualitative abnormality in the expression deletion analysis 13, 14 .
body-based dystrophin analysis. Here we identify two
where in vitro degradation of dystrophin and DRP was cases where in vitro protein degradation caused diagrecognized [10] [11] [12] . Further, we experimentally deter- ing has led to the recognition that the phenotypic range three maternal generations there had been various undiagnosed of this disease is considerably wider than previously complaints involving the neuromuscular system. Physical examinabelieved [1] [2] [3] [4] [5] [6] [7] . Current DNA-based tests can detect ge-tion revealed normal muscle bulk and strength, however, deep tendon reflexes were hypoactive. Laboratory evaluation included elecnetic mutations in only Ç65% of D/BMD cases while tromyography which was normal and histopathological studies on the sensitivity of antibody-based tests that analyzes quadriceps muscle biopsy which revealed mild type 1 fiber grouping the protein, approaches 100%. Thus the laboratory ver-on light microscopy. No significant ultrastructural abnormalities ification of D/BMD in Ç35% of cases, relies solely upon were noted on electron microscopy. Serum chemistry revealed a mild elevation of Creatine kinase 58 IU (normal õ30 IU; EC 2.7. X) and DRP (chromosome 6) were normal. A sample of quadriceps muscle was found to have normal appearance on histochemistry and muscle fiber differentiation was appropriate for gestational age. Over 10 hours passed between the abortion and processing of tissue.
Control muscle. Previously characterized muscle biopsies from patients with unrelated neuromuscular disorders. Controls had normal dystrophin and DRP levels. mdx B10 mice were sacrificed, muscle rapidly removed and flash-frozen, prior to analysis.
In vitro degradation. Flash-frozen muscle was rapidly solubilized in 20 volumes sample buffer (10% SDS, 0.1 M Tris [pH 8.0], 10 mM EDTA, bromophenol blue and 50 mM DTT) using a teflon coated pestle. Muscle was incubated at 37ЊC for varying periods of time after which samples were rapidly frozen on solid carbon dioxide.
RESULTS
Case A. To exclude the possibility of sub-clinical or an unusual presentation of D/BMD, dystrophin testing was performed on a portion of a preexisting diagnostic muscle biopsy from this case. No dystrophin was detected on immunoblots using the 60 kDa dystrophin antibody 15 . Since the laboratory finding that suggested DMD was discordant with the patient's clinical presentation, we repeated the immunoblot analysis with the originally tested sample and a fresh sample from the same biopsy. The repeat test revealed the absence of a full size dystrophin band and the presence of multiple degradation fragment bands of lower molecular mass on using d6-10, a different dystrophin antibody ( Figure  1A ; Lane 2) 16 . On testing a fresh aliquot of the biopsy, a faint band of appropriate size for dystrophin (Ç400 kDa) was noted ( Figure 1A ; Lane 3). A parallel blot was probed with DRP antibodies revealing a lack of the co-migratory DRP band in the original sample and an extremely faint band in the fresh aliquot ( Figure   FIG. 1 . Lanes 1 and 4 contain trophin labeling was detected, however, no DRP label-two different control samples, lanes 2 and 3 contain two pieces of ing was seen, suggesting that DRP degradation oc-the same biopsy from case A, described in materials and methods. curred before dystrophin degradation in this biopsy 16, 17 . Lane 2 contains the originally tested portion and demonstrates presence of multiple degradation bands and absence of DRP and dysImmunoblotting revealed subtle degradative changes trophin. Lane 3 demonstrates less severe protein degradation as eviin both proteins as well (Fig. 2) .
denced by discernible, though fainter, dystrophin and DRP staining and fewer degradation bands.
Control muscle. Since DRP appeared to be a sensitive indicator of muscle sample integrity, we analyzed the time course of DRP and dystrophin degradation in a previously characterized muscle biopsy. The sample DISCUSSION was solubilized and analyzed at various time points after thawing. Full length dystrophin was undetectable Dystrophin testing has become an integral part of the diagnostic workup of a patient with possible D/BMD. The by approximately 45 minutes at 37Њ, while DRP degradation occurred with a faster time course such that demonstration of a dystrophinopathy along with clinical and histopathological findings, are considered indicative DRP was undetectable by 30 minutes (Figure 3) . Similar studies on muscle from dystrophin deficient mdx of X-linked D/BMD 1 . In unusual, albeit rarer presentations of D/BMD such as congestive cardiac failure, or limb mice, were used to exclude dystrophin cross reactivity and a similar time course of degradation was observed weakness in females, dystrophin abnormalities may in fact be the only objective evidence of the disease [3] [4] [5] [6] [7] . Al-(data not shown).
FIG. 2.
Immunohistochemical analysis of dystrophin and DRP in a 30-wk-old abortus. Cryostat sections were cut from fetal quadriceps muscle and labeled with dystrophin and DRP antibodies and visualized by indirect immunofluorescent microscopy as described for adult tissue. Top panel demonstrates the sarcolemmal labelling obtained using dystrophin (DYS) antibodies. Absence of DRP labeling is evident in the lower panel. Total magnification is 4401.
though, the dystrophin immunoblot is an objective test, a primary genetic cause, there must be some assurance about the integrity of the biopsy being tested. unrecognized in vitro degradation of dystrophin may result in a false positive diagnosis of D/BMD. Thus, to deFor purposes of dystrophin analysis adequate integrity can be assumed provided that care has been taken to termine that the absence of dystrophin is indeed due to tive marker for protein degradation. In addition DRP is known to be of a similar size and expressed in a majority of patients of D/BMD, hence fulfilling the criteria for a degradation marker 11, 12, 17, 19 . In this study we used DRP as a marker to determine that the probable cause of absence of dystrophin in one patient was in vitro degradation rather than a genetic mutation, hence avoiding a potential misdiagnosis. Since DRP evaluation can even be performed on old, previously processed dystrophin immunoblots, it should be possible to correct previous false positive D/BMD diagnosis without either a repeat biopsy or long term follow up. We therefore suggest that the concomitant or sequential usage of DRP antibodies along with dystrophin antibodies while analyzing unusual/atypical cases of D/BMD can reduce misdiagnoisis of this disease. 
